Miruvor
Sign up
The short answer

What studies of probiotics and fermented foods found

48papers on probiotics and fermented foods
184people in 10 studies testing probiotics and fermented foods alone
6randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, the placebo trial (low certainty): 2 findings, all B.

9 outcomes rated · see each below

ME/CFS: D Little or no difference

Based on the strongest evidence, the placebo trial and studies with no comparison group (very low certainty): 4 of 6 findings are D.

6 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for fatigue.

1 outcome rated · see each below

Preventing long COVID: A Probably helps

Based on the strongest evidence, the placebo trial (moderate certainty), for overall symptoms.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, probiotics and fermented foods may help, but the evidence is still limited. For ME/CFS, studies found little or no difference with probiotics and fermented foods. For long COVID and ME/CFS studied together, probiotics and fermented foods might help some people, but research can’t show it yet. For preventing long COVID, studies show probiotics and fermented foods probably helps. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 48 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. Probiotics and fermented foods · Preventing long COVID is hereA
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Probiotics and fermented foods · Long COVID is hereB
    May helpImprovement, low certainty
  3. Probiotics and fermented foods · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Probiotics and fermented foods · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue3 studies · 38 people took probiotics and fermented foods Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: some concerns about bias (RoB 2); few people (87 in all); the studies disagree.

Placebo trials2 studies · 87 people with results

Studies disagree about fatigue.

Studies disagree about whether probiotics and fermented foods helps fatigue. Mixed results · very low certainty C

  • Some concerns about bias (RoB 2)
  • Few people (87 in all)
  • The studies disagree

Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · one capsule containing 2.5 × 109 CFU, twice daily for 3 months (few people)

Fatigue improved.

The evidence is very uncertain about the effect of probiotics and fermented foods on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): alleviation of fatigue, better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Combination: Lactoferrin and colostrum + Probiotics and fermented foods200 randomised

A Randomized Controlled Trial of the Efficacy of Systemic Enzymes and Probiotics in the Resolution of Post-COVID Fatigue. (2021): physical fatigue, better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 3 studies
  1. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial. (2026)

    People in the study
    53 randomised · 48 analysed
    Dose
    450 billion CFU/sachet, two sachets/day for 28 days
    Outcome
    CFS score change Chalder Fatigue Scale
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Efficacy of heat-treated Lacticaseibacillus paracasei PS23 for individuals with long coronavirus disease-19 syndrome: a double-blinded randomized control pilot study. (2026)

    People in the study
    39 randomised
    Dose
    10 billion heat-treated cells, two capsules daily
    Outcome
    Fatigue
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  3. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)

    People in the study
    1 in the study
    Dose
    one capsule containing 2.5 × 109 CFU, twice daily for 3 months
    Outcome
    fatigue
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 14 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (39 in all).

The placebo trial39 randomised · six weeks · 10 billion heat-treated cells, two capsules daily

Cognition (brain fog) improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (39 in all)

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): memory loss, better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 1 study
  1. Efficacy of heat-treated Lacticaseibacillus paracasei PS23 for individuals with long coronavirus disease-19 syndrome: a double-blinded randomized control pilot study. (2026)

    People in the study
    39 randomised
    Dose
    10 billion heat-treated cells, two capsules daily
    Outcome
    CTT2 Color Error Color Trails Test
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Pain2 studies · 33 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 77 people in all; a small benefit can't be ruled out.

Placebo trials2 studies · 77 people with results

No clear difference in pain.

The evidence is very uncertain about the effect of probiotics and fermented foods on pain in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 77 people in all; a small benefit can't be ruled out

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): joint pain, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 2 studies
  1. Efficacy of heat-treated Lacticaseibacillus paracasei PS23 for individuals with long coronavirus disease-19 syndrome: a double-blinded randomized control pilot study. (2026)

    People in the study
    39 randomised
    Dose
    10 billion heat-treated cells, two capsules daily
    Outcome
    Abdominal Pain
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. The Role of VSL#3® in the Treatment of Fatigue and Other Symptoms in Long Covid-19 Syndrome: a Randomized, Double-blind, Placebo-controlled Pilot Study (DELong#3) (2023) preprint

    People in the study
    39 randomised · 38 started · 38 analysed
    Dose
    total of 450 billion CFU/sachet, 2 sachets/die for 28 days
    Outcome
    SF-36 Pain Short Form-36
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 19 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 38 people found no clear difference; a small benefit can't be ruled out.

The placebo trial39 randomised · 38 started · 38 analysed · 4 weeks · total of 450 billion CFU/sachet, 2 sachets/die for 28 days

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of probiotics and fermented foods on low mood or anxiety in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 38 people found no clear difference; a small benefit can't be ruled out

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): mood disturbance, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 1 study
  1. The Role of VSL#3® in the Treatment of Fatigue and Other Symptoms in Long Covid-19 Syndrome: a Randomized, Double-blind, Placebo-controlled Pilot Study (DELong#3) (2023) preprint

    People in the study
    39 randomised · 38 started · 38 analysed
    Dose
    total of 450 billion CFU/sachet, 2 sachets/die for 28 days
    Outcome
    HADS-A Hospital Anxiety and Depression Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Autonomic symptoms1 study · 14 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 39 people found no clear difference; a small benefit can't be ruled out.

The placebo trial39 randomised · six weeks · 10 billion heat-treated cells, two capsules daily

No clear difference in autonomic symptoms.

The evidence is very uncertain about the effect of probiotics and fermented foods on autonomic symptoms in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 39 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Efficacy of heat-treated Lacticaseibacillus paracasei PS23 for individuals with long coronavirus disease-19 syndrome: a double-blinded randomized control pilot study. (2026)

    People in the study
    39 randomised
    Dose
    10 billion heat-treated cells, two capsules daily
    Outcome
    Palpitations
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Depression1 study · 14 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 39 people found no clear difference; a small benefit can't be ruled out; only people who finished were analysed.

The placebo trial39 randomised · six weeks · 10 billion heat-treated cells, two capsules daily

No clear difference in depression.

The evidence is very uncertain about the effect of probiotics and fermented foods on depression in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 39 people found no clear difference; a small benefit can't be ruled out
  • Only people who finished were analysed
See the 1 study
  1. Efficacy of heat-treated Lacticaseibacillus paracasei PS23 for individuals with long coronavirus disease-19 syndrome: a double-blinded randomized control pilot study. (2026)

    People in the study
    39 randomised
    Dose
    10 billion heat-treated cells, two capsules daily
    Outcome
    PHQ-9 Total Patient Health Questionnaire-9
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning2 studies · 24 people took probiotics and fermented foods Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (48 in all).

The placebo trial53 randomised · 48 analysed · 4 weeks · 450 billion CFU/sachet, two sachets/day for 28 days

Daily functioning improved more than in the comparison group.

Probiotics and fermented foods may improve daily functioning in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (48 in all)

Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · one capsule containing 2.5 × 109 CFU, twice daily for 3 months (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of probiotics and fermented foods on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): ability to exercise, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 2 studies
  1. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial. (2026)

    People in the study
    53 randomised · 48 analysed
    Dose
    450 billion CFU/sachet, two sachets/day for 28 days
    Outcome
    Physical functioning variation % Short Form-36 Health Survey
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)

    People in the study
    1 in the study
    Dose
    one capsule containing 2.5 × 109 CFU, twice daily for 3 months
    Outcome
    Bell CFIDS disability scale
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms2 studies · 24 people took probiotics and fermented foods Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (48 in all); effect size 0.74 (moderate).

The placebo trial53 randomised · 48 analysed · 4 weeks · 450 billion CFU/sachet, two sachets/day for 28 days

Overall symptoms improved more than in the comparison group.

Probiotics and fermented foods may improve overall symptoms in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (48 in all)
  • Effect size 0.74 (moderate)

How big was the difference?

0.74, moderate. The effect size compares probiotics and fermented foods with placebo.

Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · one capsule containing 2.5 × 109 CFU, twice daily for 3 months (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of probiotics and fermented foods on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): general unwellness, better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 2 studies
  1. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial. (2026)

    People in the study
    53 randomised · 48 analysed
    Dose
    450 billion CFU/sachet, two sachets/day for 28 days
    Outcome
    proportion of responders
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)

    People in the study
    1 in the study
    Dose
    one capsule containing 2.5 × 109 CFU, twice daily for 3 months
    Outcome
    reduction in symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life2 studies · 33 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 77 people in all; a small benefit can't be ruled out; only people who finished were analysed.

Placebo trials2 studies · 77 people with results

No clear difference in quality of life.

The evidence is very uncertain about the effect of probiotics and fermented foods on quality of life in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 77 people in all; a small benefit can't be ruled out
  • Only people who finished were analysed
See the 2 studies
  1. Efficacy of heat-treated Lacticaseibacillus paracasei PS23 for individuals with long coronavirus disease-19 syndrome: a double-blinded randomized control pilot study. (2026)

    People in the study
    39 randomised
    Dose
    10 billion heat-treated cells, two capsules daily
    Outcome
    Q-LES-Q Overall Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. The Role of VSL#3® in the Treatment of Fatigue and Other Symptoms in Long Covid-19 Syndrome: a Randomized, Double-blind, Placebo-controlled Pilot Study (DELong#3) (2023) preprint

    People in the study
    39 randomised · 38 started · 38 analysed
    Dose
    total of 450 billion CFU/sachet, 2 sachets/die for 28 days
    Outcome
    SF-36 Role limitation due to Emotional Problems Short Form-36
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

ME/CFS

Symptoms

Anxiety1 study · 19 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (35 in all); only people who finished were analysed.

The placebo trial39 randomised · 35 analysed · 8 weeks · 8 billion cfu per sachet; total 24 billion cfu per day, After each main meal, or three times daily

Anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on anxiety in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (35 in all)
  • Only people who finished were analysed
See the 1 study
  1. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. (2009)

    People in the study
    39 randomised · 35 analysed
    Dose
    8 billion cfu per sachet; total 24 billion cfu per day, After each main meal, or three times daily
    Outcome
    anxiety symptoms Beck Anxiety Inventory (BAI)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Cognition (brain fog)1 study · 15 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (15 in all); not all results were tested against chance.

Studies with no comparison group15 in the study · ten weeks per participant (baseline days 0–14, treatment day 14–42, follow-up to day 70) · 10^8 colony forming units (cfu)/ml, twice daily (2 dl × 2) during 30 days with start on day 14

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of probiotics and fermented foods on cognition (brain fog) in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (15 in all)
  • Not all results were tested against chance

Combination: Erythromycin + Probiotics and fermented foods44 in the study

Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): cognitive flexibility, better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 1 study
  1. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. (2009)

    People in the study
    15 in the study
    Dose
    10^8 colony forming units (cfu)/ml, twice daily (2 dl × 2) during 30 days with start on day 14
    Outcome
    Neurocognitive functions (VAS) Visual Analogue Scales
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue2 studies · 24 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (24 in all).

Studies with no comparison group2 studies · 24 people with results

No clear change in fatigue.

The evidence is very uncertain about the effect of probiotics and fermented foods on fatigue in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (24 in all)

Combination: Erythromycin + Probiotics and fermented foods44 in the study

Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): fatigue, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 2 studies
  1. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. (2009)

    People in the study
    15 in the study
    Dose
    10^8 colony forming units (cfu)/ml, twice daily (2 dl × 2) during 30 days with start on day 14
    Outcome
    Fatigue (VAS) Visual Analogue Scales
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Modification of Immunological Parameters, Oxidative Stress Markers, Mood Symptoms, and Well-Being Status in CFS Patients after Probiotic Intake: Observations from a Pilot Study. (2019)

    People in the study
    13 in the study · 9 with outcome data
    Dose
    according to the schedule of Table 1
    Outcome
    correlation between d-ROM and Chadler's scale
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 9 (few people) people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (9 in all).

Studies with no comparison group13 in the study · 9 with outcome data · before and after probiotic administrations · according to the schedule of Table 1 (few people)

No clear change in depression.

The evidence is very uncertain about the effect of probiotics and fermented foods on depression in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (9 in all)
See the 1 study
  1. Modification of Immunological Parameters, Oxidative Stress Markers, Mood Symptoms, and Well-Being Status in CFS Patients after Probiotic Intake: Observations from a Pilot Study. (2019)

    People in the study
    13 in the study · 9 with outcome data
    Dose
    according to the schedule of Table 1
    Outcome
    correlation between d-ROM and BDI-I and BDI-II Beck Depression Inventory
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Quality of life2 studies · 24 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (24 in all).

Studies with no comparison group2 studies · 24 people with results

No clear change in quality of life.

The evidence is very uncertain about the effect of probiotics and fermented foods on quality of life in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (24 in all)
See the 2 studies
  1. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. (2009)

    People in the study
    15 in the study
    Dose
    10^8 colony forming units (cfu)/ml, twice daily (2 dl × 2) during 30 days with start on day 14
    Outcome
    SF-12 physical health SF-12 Health Survey
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Modification of Immunological Parameters, Oxidative Stress Markers, Mood Symptoms, and Well-Being Status in CFS Patients after Probiotic Intake: Observations from a Pilot Study. (2019)

    People in the study
    13 in the study · 9 with outcome data
    Dose
    according to the schedule of Table 1
    Outcome
    correlation between d-ROM and PCS indexes Short Form Health Survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning1 study · 15 people took probiotics and fermented foods Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (15 in all).

Studies with no comparison group15 in the study · ten weeks per participant (baseline days 0–14, treatment day 14–42, follow-up to day 70) · 10^8 colony forming units (cfu)/ml, twice daily (2 dl × 2) during 30 days with start on day 14

No clear change in daily functioning.

The evidence is very uncertain about the effect of probiotics and fermented foods on daily functioning in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (15 in all)
See the 1 study
  1. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. (2009)

    People in the study
    15 in the study
    Dose
    10^8 colony forming units (cfu)/ml, twice daily (2 dl × 2) during 30 days with start on day 14
    Outcome
    Physical activity scores SF-12 Health Survey
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Both together

Fatigue1 study · 26 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (26 in all).

Studies with no comparison group26 randomised · after 3 months

Fatigue improved.

The evidence is very uncertain about the effect of probiotics and fermented foods on fatigue in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (26 in all)

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): General fatigue, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 1 study
  1. The impact of a 3-month synbiotic supplementation on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients dealing with post-COVID-19 chronic fatigue syndrome (2024)

    People in the study
    26 randomised
    Dose
    —
    Outcome
    general fatigue
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Preventing long COVID

Symptoms

Fatigue2 studies · 58 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all).

The placebo trial73 randomised · 28 days · 5 billion CFU total, once daily before breakfast during the 28-day observation period

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on fatigue later, when given during acute COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)

Compared with another group, not randomised58 in the study · median: 23 days (IQR: 19–38 days · 2,400 billion bacteria per day, three equal doses per day

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on fatigue later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 2 studies
  1. The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study. (2024)

    People in the study
    73 randomised
    Dose
    5 billion CFU total, once daily before breakfast during the 28-day observation period
    Outcome
    duration of fatigue after COVID -19
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients. (2021)

    People in the study
    58 in the study
    Dose
    2,400 billion bacteria per day, three equal doses per day
    Outcome
    positive for fatigue Fatigue Assessment Scale (FAS)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; probiotic given in case of intestinal symptoms Patients admitted to the ward received supplementation with oral bacteriotherapy, in addition to the best available therapy, in case of intestinal symptoms
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Anxiety1 study · 34 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all).

The placebo trial73 randomised · 28 days · 5 billion CFU total, once daily before breakfast during the 28-day observation period

Anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on anxiety later, when given during acute COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)
See the 1 study
  1. The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study. (2024)

    People in the study
    73 randomised
    Dose
    5 billion CFU total, once daily before breakfast during the 28-day observation period
    Outcome
    duration of anxiety after COVID -19
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Breathlessness1 study · 34 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all); effect size 0.77 (moderate).

The placebo trial73 randomised · 28 days · 5 billion CFU total, once daily before breakfast during the 28-day observation period

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on breathlessness later, when given during acute COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)
  • Effect size 0.77 (moderate)

How big was the difference?

0.77, moderate. The effect size compares probiotics and fermented foods with placebo.

See the 1 study
  1. The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study. (2024)

    People in the study
    73 randomised
    Dose
    5 billion CFU total, once daily before breakfast during the 28-day observation period
    Outcome
    respiratory symptoms at day 10
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Daily life and health overall

Overall symptoms1 study · 34 people took probiotics and fermented foods Improvement A
Moderate certainty

Why this grade: Improvement, moderate certainty, from randomised trials: few people (73 in all); effect size 0.90 (large).

The placebo trial73 randomised · 28 days · 5 billion CFU total, once daily before breakfast during the 28-day observation period

Overall symptoms improved more than in the comparison group.

Probiotics and fermented foods probably improves overall symptoms later, when given during acute COVID. Improvement · moderate certainty A

  • Few people (73 in all)
  • Effect size 0.90 (large)

How big was the difference?

0.9, large. The effect size compares probiotics and fermented foods with placebo.

Combination: Probiotics and fermented foods + Baicalein and quercetin + Butyrate (sodium butyrate, tributyrin)52 randomised

Efficacy of a Multistrain Synbiotic Treatment in Acute and Post-Acute COVID-19 Patients: A Double-Blind, Placebo-Controlled Randomized Trial. (2024): disease-related symptoms, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

See the 1 study
  1. The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study. (2024)

    People in the study
    73 randomised
    Dose
    5 billion CFU total, once daily before breakfast during the 28-day observation period
    Outcome
    global symptom score on day 10
    Effect
    better
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Daily functioning1 study · 34 people took probiotics and fermented foods Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all); effect size 0.72 (moderate).

The placebo trial73 randomised · 28 days · 5 billion CFU total, once daily before breakfast during the 28-day observation period

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of probiotics and fermented foods on daily functioning later, when given during acute COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)
  • Effect size 0.72 (moderate)

How big was the difference?

0.72, moderate. The effect size compares probiotics and fermented foods with placebo.

See the 1 study
  1. The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study. (2024)

    People in the study
    73 randomised
    Dose
    5 billion CFU total, once daily before breakfast during the 28-day observation period
    Outcome
    case severity according to the WHO’s ordinal severity scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Studies of combinations

Outcomes that only studies of probiotics and fermented foods given together with other treatments looked at. Shown, not graded: they can’t tell what probiotics and fermented foods did alone.

Breathlessness Long COVID

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): shortness of breath, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Sleep Long COVID

Combination: Probiotics and fermented foods463 randomised

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. (2024): insomnia, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Cognition (brain fog) Preventing long COVID

Combination: Probiotics and fermented foods + Baicalein and quercetin + Butyrate (sodium butyrate, tributyrin)52 randomised

Efficacy of a Multistrain Synbiotic Treatment in Acute and Post-Acute COVID-19 Patients: A Double-Blind, Placebo-Controlled Randomized Trial. (2024): neurological/neurocognitive symptoms, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Overall symptoms ME/CFS

Combination: Erythromycin + Probiotics and fermented foods44 in the study

Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): self-reported total symptoms (SSH), better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Daily functioning Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Time to exhaustion (sec), no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Smell and taste loss Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Anosmia, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Pain Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Lung pain, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Breathlessness Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Breathing difficulties, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Cognition (brain fog) Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Difficulties concentrating, no clear difference.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Post-exertional malaise Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Post-exercise malaise, better.

Shown, not counted: probiotics and fermented foods was given together with other treatments.

Side effects

Stopping because of side effects3 studies
Side effects studies reported3 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue2 studies
Nausea or stomach upset2 studies
Worse symptoms or a flare2 studies

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    250 mg at the start

  2. 2Top dose

    Most often 250 mg (1 of 1 studies)

Doses across 1 study

250 to 250 mg.

Each study’s dose, as printed

All papers

  1. The Impact of Psychobiotic Therapy on Anxiety and Depressive Symptoms in Patients with Post-COVID Syndrome-A Randomized, Double-Blind, Placebo-Controlled Trial.2026 · placebo trial · 62 randomised · 56 analysed
    Summary

    This randomized, double-blind, placebo-controlled trial asked whether a psychobiotic would reduce anxiety and depressive symptoms in people recovering from COVID-19 with post-COVID syndrome and anxiety and/or depressive symptoms. Participants were recruited among individuals admitted to the post-COVID department of the Complex of Healthcare Institutions in Czarnków, Poland. A total of 62 participants were randomized: 32 to the psychobiotic group and 30 to the control group. The psychobiotic group received 1 capsule each day containing 3 × 109 CFU Lactobacillus helveticus Rosell®–52 and Bifidobacterium longum Rosell®–175 for 6 weeks; the control group received an identical placebo capsule. Fifty-six participants completed the study and were included in the analysis, 28 per group. Six individuals did not attend the visit after supplementation and gave no reason. Outcomes included HADS, GAD-7, BDI and SCL-90 scores and fecal short-chain fatty acids. At baseline, median HADS-D, HADS-A, GAD-7, and BDI levels did not differ significantly between groups. After supplementation, median depression and anxiety levels were significantly lower in the psychobiotic group than in the control group; the abstract reports a 57.2% reduction in anxiety severity (GAD-7) and a 50.9% reduction in depressive symptoms (BDI), with p = 0.0001 for HADS-D, HADS-A and GAD-7 and p = 0.0003 for BDI. Prevalence of anxiety and depressive symptoms decreased in the psychobiotic group (HADS-A p = 0.0044; GAD-7 p = 0.0219; BDI p = 0.0011). None of the patients who completed the study reported any adverse events.

  2. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.2026 · placebo trial · 53 randomised · 48 analysed
    Summary

    The DELong#3 trial asked whether VSL#3® could reduce fatigue in long COVID. It enrolled 53 adults with long COVID and clinically relevant fatigue at a Long COVID Outpatient Clinic in Milan, Italy, between November 2022 and November 2023; 48 were analysed (25 placebo, 23 VSL#3®). Participants received VSL#3® (450 billion CFU/sachet) or placebo, two sachets/day for 28 days (4 weeks), with an additional 4-week follow-up. The primary measure was the Chalder Fatigue Scale (CFS); secondary questionnaires included SF-36, SAGIS, HADS, SCL-12, KPS and VAS, plus exploratory microbiota, immune and metabolomic analyses. The CFS change was 24.24 with VSL#3® versus 6.06 with placebo (p = 0.037), and responders were 68% versus 35.7% (p = 0.019). The CFS improvement was maintained at follow-up in the VSL#3® group, whereas no significant changes were observed in the placebo group. SF-36 fatigue variation was 10 versus 0 (p = 0.0637), not significant. Physical functioning and role limitation due to emotional problems differed (p = 0.03738 for both). No statistically significant differences were detected across other clinical questionnaires. No clinically relevant adverse events were reported; five participants were excluded due to low adherence. The authors state limitations including the relatively small cohort size, the limited duration of the post-treatment follow-up, the exploratory nature of the multi-omic analyses, and the lack of vaccination-status stratification.

  3. Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study.2024 · placebo trial · 36 randomised
    Summary

    This randomized, placebo-controlled pilot study asked whether a multispecies probiotic could modulate the gut–lung axis in post-acute COVID-19. It included 36 patients at the Medical University of Graz: 10 after mild COVID-19 infection and 26 after severe COVID-19 infection. The 26 severe patients were randomized, 13 to probiotic (OMNi-BiOTiC® Pro-Vi 5) twice a day and 13 to placebo twice a day, in a six-month intervention; patients after mild disease served as non-randomized controls. Eight patients in the probiotic group and 13 in the placebo group finished per protocol and were included in the analysis. Five patients in the probiotic group dropped out; four of the five dropouts were directly or indirectly related to the study, with burden of the study, taste of the study product, and mild gastrointestinal complaints as reasons. Outcomes included quality of life questionnaires and routine laboratory parameters. Patients in the probiotic group felt significantly less tired on the ARTIQ after 3 months (p = 0.014), but after 6 months this was only a trend (p = 0.07). Psychological burden significantly improved after 3 months of probiotic intervention (p = 0.022). No other significant changes between probiotic- and placebo-treated patients were observed over time in the quality of life questionnaires. The authors state the study is limited by a small sample size and was designed as a pilot.

  4. The impact of a 3-month synbiotic supplementation on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients dealing with post-COVID-19 chronic fatigue syndrome2024 · placebo trial · 26 randomised
    Summary

    This parallel-group, randomized, placebo-controlled, double-blind trial examined a 3-month synbiotic supplementation in twenty six adults with post-COVID-19 ME/CFS. The synbiotic mixture included L. rhamnosus DSM 32550, Humiome® L. plantarum DSM 34532, B. lactis DSM 32269, B. longum DSM 32946, fructooligosaccharides and zinc; it was compared with placebo. The authors report that both the synbiotic and placebo intake resulted in a significant reduction in general fatigue after 3 months compared to baseline values (P ≤ 0.05). They also report a significant interaction effect (time vs. treatment) for post-exercise malaise (P = 0.02), with synbiotic superior to placebo to attenuate post-exercise malaise. The abstract lists patient-reported outcomes, exercise tolerance, and tissue metabolism as outcome areas. Harms, side effects, and withdrawals were not reported in the available text. No information on people who worsened or stopped was reported. The authors conclude that taking the synbiotic mixture for three months improves tissue metabolism and mitigates clinical features of post-COVID-19 fatigue syndrome, but state that further validation is needed before endorsing synbiotics within this clinical context. Study setting and per-arm numbers were not reported in the available text.

  5. The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study.2024 · placebo trial · 73 randomised
    Summary

    This multicenter, randomized, double-blind, placebo-controlled, prospective, parallel-group study enrolled symptomatic outpatients with acute COVID-19 from primary care and outpatient practices. Seventy-three patients were randomized to probiotic (n = 36) or placebo (n = 37); 73 were assessed for clinical endpoints and 44 for antibody production. Patients took 1 capsule a day for 28 days and completed the Post-COVID-19 Questionnaire three months later. On day 10, the median global symptom score was 0.0 (0.0–2.0) in the probiotic group vs. 2.0 (1.0–5.0) with placebo (P < 0.05); constitutional symptoms were 0.0 (0.0–1.0) vs. 1.0 (0.0–2.0) (P = 0.018), respiratory symptoms 0.0 (0.0–1.0) vs. 1.0 (0.0–2.5) (P = 0.006), and gastrointestinal symptom scores did not differ (0.0 (0.0–0.0) vs. 0.0 (0.0–0.0), P = 0.704). Symptom duration was 11.0 (7.0–17.0) vs. 14.0 (12.0–20.0) days (P = 0.035). No patients were hospitalized in either group. Few adverse events were reported; urticarial rash occurred in two probiotic and one placebo patient and lasted 1–3 days, and one probiotic patient discontinued taking TDS and dropped out due to rash; all recorded adverse events were unrelated to the TDS. Three probiotic patients did not return the RID, five patients refused the second blood draw, 21 were unavailable due to force majeure, and one placebo patient did not return PCQ-19.

  6. The Role of VSL#3® in the Treatment of Fatigue and Other Symptoms in Long Covid-19 Syndrome: a Randomized, Double-blind, Placebo-controlled Pilot Study (DELong#3)2023 · placebo trial · 39 randomised · 38 started · 38 analysed · preprint
    Summary

    The study asked whether VSL#3®, a multi-strain probiotic, reduces fatigue and other symptoms in Long COVID. It was a phase three, single-center, randomized, double-blind, placebo-controlled trial at the LC Outpatient Clinic at Policlinico Hospital, Milan (Italy). A total of 39 individuals with clinically significant fatigue were selected; 38 were recorded as started and analysed (19 VSL#3®, 19 placebo). Participants received VSL#3® or placebo for 4 weeks, 2 sachets/die for 28 days, with 4 additional weeks of follow-up after the end of treatment. The primary endpoint was Chalder Fatigue Scale score after 4 weeks; secondary outcomes included SF-36, SAGIS, HADS, SCL-90 somatization, KPS and VAS. For the Chalder Fatigue Score, the median variation % was -24 (-60.9;-11.6) with VSL#3® versus -4.4 (-18.8;0.0) with placebo, p=0.0079, and the significant reduction persisted 4 weeks post treatment. SF-36 Fatigue (p=0.0279) and Physical functioning (p=0.0193) showed significant amelioration; other SF-36 domains were not significantly different. SAGIS total improved significantly (p=0.0429), while nausea and vomiting, constipation, epigastric pain and IBS symptoms did not vary between arms; acid regurgitation was reported both as not varying and with p=0.0159. HADS-A, HADS-D, SCL-12, KPS and VAS did not differ. No clinically relevant adverse events were reported during the intervention; one participant was dismissed due to low adherence.

  7. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome.2009 · placebo trial · 39 randomised · 35 analysed
    Summary

    This randomized, double-blind, placebo-controlled pilot study asked whether oral probiotics affect emotional symptoms in chronic fatigue syndrome (CFS). Candidates were screened from a pool of CFS patients in a tertiary setting; 39 were randomized to Lactobacillus casei strain Shirota (LcS) or placebo for 8 weeks. The active group consumed 24 billion colony forming units of LcS daily by mouth, three times daily after meals; placebo had identical taste and appearance. Beck Depression and Beck Anxiety Inventories and stool samples were collected before and after the intervention. Thirty-five patients, 27 females and 8 males, completed the 8-week investigation. Four patients withdrew, two from the LcS group and two from the placebo group, for reasons unrelated to the intervention. The authors reported no significant adverse events in either group. Anxiety symptoms decreased significantly among those taking the probiotic versus controls (p = 0.01). For the BAI, the probiotic pre-versus-post result was p = 0.011. The BDI difference did not reach statistical significance (p = 0.292). The authors state that this is a small pilot study and broad conclusions cannot be drawn; they also note that bowel function was not evaluated.

  8. Rationale for the use of a fifth-generation multisymbiotic in medical rehabilitation of patients with post-acute COVID-19 syndrome2025 · randomised trial · 128 randomised
    Summary

    Post-acute COVID-19 syndrome is described as a major healthcare challenge associated with gut dysbiosis, and the study aimed to establish clinical and laboratory rationale for adding the fifth-generation multisymbiotic VedaBiotic to medical rehabilitation. The abstract reports 128 patients with post-acute COVID-19 syndrome; group I is printed as n = 64 and group II as n = 32. Group I received therapeutic exercise, classic manual thoracic massage, dry carbon dioxide baths, pulsed electrostatic therapy to the chest using the Hivamat device, and biofeedback-assisted respiratory training, performed as 9 daily sessions. Group II received the same programme and additionally oral fifth-generation multisymbiotic VedaBiotic, 2 capsules once daily after breakfast. The comparison was between these rehabilitation programmes. The abstract states that efficacy was assessed by changes in clinical symptoms and relevant laboratory inflammatory markers. It states that adding the multisymbiotic into the rehabilitation program "results in a pronounced anti-inflammatory and antithrombotic effect, optimizes lipid peroxidation and antioxidant defense systems, and ensures a significant regression of clinical manifestations." No numerical results are reported. Side-effect counts, harms, and withdrawals for harms are not reported. Numbers analysed, follow-up, setting, and authors' stated limitations are not reported.

  9. Multi-Strain Probiotic Improves Tryptophan Metabolism and Symptoms in Chronic Fatigue Syndrome Patients with Co-Occurring Irritable Bowel Syndrome: An Open-Label Pilot Study.2026 · compared with another group · 40 in the study
    Summary

    The authors studied a multi-strain probiotic in women with chronic fatigue syndrome (CFS) and co-occurring IBS-U and confirmed dysbiosis. Seventy-three patients were screened at a Department of Gastroenterology outpatient clinic, and 40 female patients were enrolled and completed a 12-week intervention with the CDS22 formula at 450 billion CFU/day, taken as one sachet daily in the morning. The study compared these patients with 40 age-matched healthy women. Fatigue severity was measured with the Fatigue Severity Scale (FSS), and gastrointestinal symptoms and sleep disturbances were recorded. The mean FSS score declined from 38.0 ± 8.8 at baseline to 22.7 ± 5.3 at week 12, a 40.3% reduction relative to baseline. By week 12, 39 of 40 patients (97.5%) reached the remission threshold (FSS < 36), compared with 18 (45.0%) at baseline, and 35 patients (87.5%) achieved a reduction of ≥10 FSS points. Bloating and abdominal pain improved in the majority of participants; sleep disturbances persisted in the majority. Transient mild-to-moderate constipation and bloating were reported by 6 patients (15%) in the second week, and constipation worsened in 6 patients (15%), needing temporary laxative use. No dropouts or serious adverse events necessitating withdrawal were recorded. The authors state limitations including an open-label design, a sample size of 40, only female participants, urine-only measurements, unmonitored dietary FODMAP content, and unknown durability.

  10. Multi-Strain Probiotic Intervention Modestly Modulates Microbial Composition and Inflammatory Profile in Individuals with Long COVID.2026 · compared with another group · 90 in the study · 74 with outcome data
    Summary

    This study asked whether a 12-week multi-strain probiotic (Saccharomyces boulardii DBVPG-6763, Lacticaseibacillus rhamnosus GG, Lactiplantibacillus plantarum LP6595 and L. plantarum HEAL9; at least ≥8.5 × 109 CFUs daily) changed gut microbiota and biochemical markers in adults with long COVID or after recovery, compared with non-supplemented controls. A total of 90 adults were recruited at University Hospital Medical Center Bežanijska Kosa, Belgrade, Serbia, between January and June 2023. Of these, 16 participants were excluded due to unclear sample labeling (n = 9) or incomplete paired sampling (n = 7); 74 paired samples were analysed: 34 probiotic recipients (13 with long COVID and 21 convalescent) and 40 non-supplemented controls (10 with long COVID). Allocation was non-random. The paper reports no statistically significant differences in alpha diversity (p > 0.05 for all comparisons) or beta diversity (Bray–Curtis F = 0.83, p = 0.422). Marvinbryantia relative abundance increased (LFC = 1.57, p = 0.019), Bifidobacterium increased (Δ probiotic = 0.0264, Δ control = −0.0067, p = 0.0371), and Prevotella_9 was lower after probiotic supplementation (Δ probiotic = 0.019, Δ control = −0.030, p = 0.013). In long COVID, several genera were enriched (Adlercreutzia p = 0.013; Ruminococcaceae DTU089 p = 0.017; Negativibacillus p = 0.024; Eubacterium xylanophilum group p = 0.024; unclassified Tannerellaceae p = 0.028). CRP showed a borderline reduction (r = −0.405, p = 0.058); long COVID trends for ALT, AST, CRP and ferritin were p < 0.1. Harms were not reported. Authors note modest sample size, non-randomized design and functional prediction from 16S rRNA data.

  11. Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients.2021 · compared with another group · 58 in the study
    Summary

    Researchers conducted a retrospective observational study of 58 patients hospitalized with confirmed COVID-19 and discharged to home care. The aim was to assess fatigue six months after discharge. During hospitalization, 24 patients received oral bacteriotherapy with SLAB51 (2,400 billion bacteria per day, in three equal doses) for a median of 23 days plus best available therapy, while 34 received only standard treatment. Six months after discharge, participants completed the Fatigue Assessment Scale (FAS). Overall, 41 of 58 patients (70.7%) reported fatigue. A significantly higher proportion of patients in the standard-treatment group reported fatigue than those also treated with SLAB51: 31/34 (91%) vs 10/24 (41.7%), p < 0.01. Among fatigued patients, FAS scores were lower with SLAB51 than without: median 24 (IQR 22.5–26) vs 34 (IQR 31.5–38), p = 0.02. Extreme fatigue was reported by 1/24 (4.2%) with SLAB51 versus 10/34 (29.4%) without (p = 0.047). In a subanalysis excluding ICU patients, fatigue was 9(37.5%) with SLAB51 versus 24(70.58%) without (p = 0.0003), and FAS scores were 24 versus 33 (p = 0.007). Harms and withdrawals were not reported. The authors list observational design and lack of control, randomization, and blinding as major limitations.

  12. Synbiotic Supplementation Improves Quality of Life and Inmunoneuroendocrine Response in Patients with Fibromyalgia: Influence of Codiagnosis with Chronic Fatigue Syndrome.2023 · no comparison group · 15 in the study
    Summary

    This pilot study enrolled 15 women diagnosed with fibromyalgia (FM), 7 with and 8 without a previous diagnosis of chronic fatigue syndrome (CFS), from an FM association in Badajoz, Extremadura (Spain). Participants took the synbiotic Gasteel Plus® as one stick a day, preferably in the morning and mixed in water, for 30 days; each was evaluated at baseline and after the intervention, which lasted one month. The study had no comparison group. Outcomes included body composition by bioimpedance, activity and sleep by accelerometry, validated questionnaires, and IL-8, IL-10, cortisol and DHEA. The paper reports statistically significant improvements in perceived depression, stress, anxiety, fatigue and fibromyalgia impact on daily activity in the total group (p < 0.05); depression and stress improved only in FM patients without CFS, while anxiety, fatigue and FM impact improved only in the FM + CFS group. No significant changes were reported in weight, body fat mass percentage, bone mass, total body water percentage or muscle mass. The visceral fat index decreased statistically significant in FM patients without a codiagnosis of CFS, but without a physiological relevance. Pain, sleep quality and gastrointestinal health improved without statistical significance. The authors state there were no detrimental changes in body composition or sleep parameters.

  13. Modification of Immunological Parameters, Oxidative Stress Markers, Mood Symptoms, and Well-Being Status in CFS Patients after Probiotic Intake: Observations from a Pilot Study.2019 · no comparison group · 13 in the study · 9 with outcome data
    Summary

    This pilot study asked whether a probiotic protocol changes immune, oxidative, mood and well-being measures in patients with CFS/ME diagnosed by Fukuda criteria at a clinic in Pavia, Italy. Thirteen patients were enrolled; four discontinued before the eight-week protocol, and analysis was performed on 9 of 13. All received a sequence of probiotic mixtures for eight weeks, with clinical questionnaires and laboratory tests before and after administration; there was no comparison group. The paper reports a progressive reduction in Chadler's fatigue score and increases in SF-36 PCS and MCS, and reductions in BDI-I and BDI-II indexes. Urinary free cortisol increased 2.3x, ESR 1.7x, DHEA-S 1.4x, and CRP fell by about 30%, with the differences reported as not statistically significant. Fecal calprotectin increased after treatment. IgM rose about 3x, while IgG and IgA showed no changes. CD4/CD8 ratio fell to a mean 1.78 vs 2.06; three patients had more than 50% reduction, one about 5%, and five were unchanged. One patient had an exacerbation of symptoms at the start and discontinued. The d-ROM and MCS correlation was p = 0.043; other correlations were nonsignificant.

  14. Improvement in Long COVID Brain Fog After Benfotiamine and Methylcobalamin Supplementation: Case Report Series and Review of the Literature2026 · case report · 3 in the study
    Summary

    This case series reports three people with Long COVID-related cognitive dysfunction (brain fog); one also had chronic fatigue syndrome/myalgic encephalomyelitis. All three self-administered an oral proprietary formulation of benfotiamine and methylcobalamin at differing doses: benfotiamine 150 mg, 300 mg, or 300 mg twice daily, with methylcobalamin 500 mcg, 1,000 mcg, or 12 mcg per day. There was no comparison group. Outcomes were patient-reported; no baseline thiamine or vitamin B12 biomarkers and no cognitive assessments were obtained before supplementation. Each patient described a noticeable benefit within a brief period ranging from several days to several weeks. In case 1, improvement in energy and mental clarity and resolution of brain fog were reported within three days. In case 2, improvements in mental clarity, executive function and confidence were reported within six weeks; after five weeks without the supplement, cognitive dysfunction recurred, and improved cognitive function returned within four to six weeks of resuming it. In case 3, brain fog and joint pain improved within 10 days, radicular pain resolved and dizziness improved by approximately 85% after 30 days. No serious adverse effects were reported by any patient; case 1 reported no adverse effects. The authors state the observations are hypothesis-generating and cannot establish causality.

  15. Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review.2026 · case report · 1 in the study
    Summary

    This case report and literature review describes one 33-year-old man with post-COVID ME/CFS admitted to Jaseng Hospital of Korean Medicine. He received vagal reflex stimulation via electroacupuncture of the deep peroneal nerve for 12 weeks (once daily for three consecutive weeks during hospitalization, then tapering). There was no comparison group. Fatigue was assessed with the Multidimensional Fatigue Inventory (total score 20–100) at baseline and at 4, 8 and 12 weeks, and flu-like symptom duration was self-recorded daily. Total MFI score declined from 71 to 31 (a reduction of more than 50%). General fatigue and reduced activity each fell −9 points; mental fatigue improved 63.6% (11 to 4) and reduced motivation 61.5% (13 to 5). General fatigue fell below the cut-off (< 13) at week 8 and reduced activity reached the threshold (< 10) at week 12. Daily flu-like symptom duration decreased from 557.1 ± 51.2 to 17.1 ± 15.8 min. Fluctuations at weeks 4 (282.9 ± 126.0 min) and 8 (285.7 ± 140.5 min) reflected transient, single-day symptom flares. No adverse events were observed. The authors state that lack of follow-up data precluded assessment of treatment durability, objective measures were not obtained, and few RCTs with small samples were included.

  16. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature.2026 · case report · 1 in the study
    Summary

    This single case report describes a 60-year-old female with long COVID who was examined at a gastroenterology outpatient clinic with chronic fatigue and autonomic dysfunction. There was no comparison group. Intestinal permeability was assessed with a carbohydrate absorption test at five different time points (IP Test 1–5), alongside fatigue and the Bell CFIDS disability scale. The patient received Innovall FD™ (Bacillus coagulans and Bacillus subtilis), one capsule containing 2.5 × 109 CFU twice daily for 3 months. During that time, her fatigue continued to subside, and the patient reported a reduction in symptoms, corresponding to an increase of around 20 on the Bell CFIDS disability scale from initial baseline of 40–60. Later, after symptoms and fatigue increased again (Bell CFIDS disability scale 40), she received medicinal clay (Luvos-Heilerde imutox™), 3 × 900 mg capsules (total 8.1 g/day) three times a day for 4 months. Within 6 months following the initiation of medicinal clay therapy, the patient experienced a remission of symptoms (Bell CFIDS disability scale 100), and in clinical follow-ups she remained in remission. The medicinal clay was discontinued to prevent potential malabsorption of nutrients associated with medicinal clay. The authors state that this is a single case report and generalizations cannot be made.

  17. S5110 Persistent Gastrointestinal Dysbiosis in a Male Patient With Post-Acute COVID-19 Syndrome: A Case Report Highlighting Microbiome-Related Sequelae2025 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes a 50-year-old man with post-acute COVID-19 syndrome, or long COVID, who had fatigue, brain fog, bloating, and new food intolerances after 8 separate SARS-CoV-2 infections. The text does not state where the patient was from. He was treated with nystatin, probiotics, enzymes, and a gluten-free, low-sugar diet. Treatment duration was not reported. There was no comparison group. Within 8 weeks, he reported improved energy, mental clarity, GI function, and food tolerance without adverse effects. The report does not provide numerical baseline or follow-up scores for these improvements, and no statistical comparison is reported. The authors state that the timing of symptom resolution after intervention supports further study; they also note that this is a single case without follow-up testing. The authors conclude that the patient’s improvement with targeted microbiome therapy highlights the potential of gut-directed care in long COVID. Limitations stated include that this is a single case without follow-up testing. The paper does not report randomisation, blinding, allocation concealment, or funding and conflicts.

  18. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial.2024 · combination: given with other treatments · 463 randomised
    Summary

    This randomised, double-blind, placebo-controlled trial at a tertiary referral centre in Hong Kong assessed SIM01 for post-acute COVID-19 syndrome (PACS) according to CDC criteria. 463 patients were randomly assigned to SIM01 (n=232) or placebo (n=231) for 6 months. SIM01 was given orally as 10 billion colony-forming units in sachets twice daily; placebo was 1 mg in sachets twice daily. The primary outcome was alleviation of PACS symptoms by 6 months, assessed by an interviewer-administered 14-item questionnaire in the intention-to-treat population. At 6 months, higher proportions of the SIM01 group had alleviation of fatigue (OR 2·273, 95% CI 1·520–3·397, p=0·0001), memory loss (1·967, 1·271–3·044, p=0·0024), difficulty in concentration (2·644, 1·687–4·143, p<0·0001), gastrointestinal upset (1·995, 1·304–3·051, p=0·0014), and general unwellness (2·360, 1·428–3·900, p=0·0008). Joint pain, ability to exercise, shortness of breath, insomnia, muscle pain, coughing, hair loss, chest pain, and mood disturbance were not significant after Bonferroni correction (p>0·0036). Quality of life visual analogue scale scores were 76·0 (SD 12·0) with SIM01 and 74·5 (12·3) with placebo (p=0·17); physical activity medians were 1646·3 and 1902·0 (p=0·37). Adverse events occurred in 22 (10%) of 232 and 25 (11%) of 231 (p=0·63), and all were deemed unlikely to be associated with the study products. Follow-up at 6 months was 204 in the SIM01 group and 199 in the placebo group.

  19. Efficacy of a Multistrain Synbiotic Treatment in Acute and Post-Acute COVID-19 Patients: A Double-Blind, Placebo-Controlled Randomized Trial.2024 · combination: given with other treatments · 52 randomised
    Summary

    Researchers tested a multistrain synbiotic (Kebirah®) in adults hospitalised with acute COVID-19 at a single Italian hospital. The trial enrolled 52 patients: 24 allocated to placebo and 28 to the probiotic group; one patient from each group was excluded from statistical analyses because faecal samples were missing. The synbiotic was taken orally once daily for 35 days and compared with placebo capsules. Outcomes included gut microbiota, blood parameters, and a questionnaire at 6 months. No serious adverse events were reported. For disease-related symptoms, the paper states no statistically significant differences between groups. For moderate to severe neurological/neurocognitive symptoms at 6 months, one sentence reports 9.1% in the probiotics group versus 35% with placebo (SMD = 0.66); the discussion reports a p value of 0.062 and SMD = 0.658, described as not reaching significance. A conflicting sentence in the same results section reports 90.9% versus 65%. The authors state the study is monocentric and call for further in vitro and in vivo models.

  20. A Randomized Controlled Trial of the Efficacy of Systemic Enzymes and Probiotics in the Resolution of Post-COVID Fatigue.2021 · combination: given with other treatments · 200 randomised
    Summary

    This randomized, multicentric, double blind, placebo-controlled trial enrolled 200 patients with post-COVID fatigue at outpatient departments at three centers in India. Patients were randomized 1:1 to a test arm (n = 100) receiving ImmunoSEB (500 mg/capsule) plus ProbioSEB CSC3 (5 billion CFUs/capsule) for 14 days, or a control arm (n = 100) receiving placebo (maltodextrin) for 14 days. Analysis was intention-to-treat, 100 patients in each arm. Fatigue was measured with the Chalder Fatigue scale (CFQ-11). On day 14, resolution of fatigue was reported in 91% vs. 15% (test vs. control). Patients fatigue free on days 4, 8, and 11 were 16% vs. 0%, 44% vs. 2%, and 87% vs. 7%. Total fatigue scores on day 4 were 23.26 vs. 18.72, day 8 21.75 vs. 14.98, day 11 20.55 vs. 10.82, and day 14 19.91 vs. 8.54 (p < 0.001), control vs. test. Physical and mental fatigue subscales showed a significantly greater reduction in the test arm at all time points (p < 0.001). No subject in either arm reported any adverse event(s) including nausea, vomiting or diarrhea at any time during the study. Authors state limitations include only a 2-week assessment, no collection of depression/psychiatric history, early timepoint average 3 weeks post resolution, no long-term follow-up, and no inflammatory/immunity markers.

  21. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons.2018 · combination: given with other treatments · 44 in the study
    Summary

    This open-label, non-randomised pilot with repeated measures and no comparison group examined an antibiotic/probiotic intervention in 44 adult ME/CFS patients (27 females) from one specialist medical clinic with Streptococcus viable counts above 3.00 × 105 cfu/g. Treatment was Erythromycin 400 mg twice daily during weeks 2 and 4, alternating with Pro4-50 d-lactate free multistrain probiotic two capsules daily during weeks 3 and 5, within a 4-week treatment protocol across 6 weeks. Outcomes included sleep, mood, cognition, fatigue, total symptoms, microbiota and urine d:l lactate ratio. Actigraphic sleep efficiency did not change (M = 83.94 to M = 83.80; partial eta squared = .03, p < .297). RVP A′ improved from M = .91 to M = .94 (partial eta squared = .53, p < .001), and SSH total symptoms reduced from M = 28.42 to M = 22.76 (partial eta squared = .29, p = .001). Mood, fatigue and urine d:l lactate ratio remained similar across time. Sex-time interactions revealed no large effects and did not support a sex-specific response. Six unexpected adverse events were reported from five participants; one discontinued all treatment after the first antibiotic dose. The authors state the open-label design and practice effects limit interpretation.

  22. Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review.2025 · systematic review
    Summary

    This systematic review asked whether dietary supplements reduce fatigue in ME/CFS. It included 14 studies (7%) identified from 189 papers searched in Ebsco Host, PubMed, Scopus, and Google Scholar; the final search was 7 May 2024. Supplements varied and included ImmunoVita®, Supradyn®, probiotics, CoQ10 with selenium or NADH, GAA, carnitine, AEO, and acclydine; treatment periods reported in the text included 36 weeks and ten weeks. Comparisons varied across the included studies. Outcomes were mainly self-report fatigue questionnaires plus quality of life, activity, and laboratory markers. Findings were mixed: some supplements were reported to reduce fatigue scores or improve cognitive fatigue, while others showed no significant fatigue changes; AEO was reported to reduce fatigue for 22–33% of participants, ENADA® showed improvement in 31%, and ALC/PLC was followed by worsening symptoms in many patients. Six out of fourteen studies reported adverse effects, including nausea, dyspepsia, insomnia, and others. The authors state no firm conclusions can be drawn due to small sample sizes and missing data, and note limitations such as focusing on fatigue as the only primary outcome.

  23. Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
    Summary

    Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.

  24. Preventive interventions for post Covid-19 condition: systematic review update2024 · systematic review · preprint
    Summary

    This systematic review update searched on February 9, 2024 and included 24 studies (5 randomized and 19 non-randomized), all among adults. It examined interventions given during acute or post-acute COVID-19 to prevent post COVID-19 condition (PCC). For convalescent plasma in outpatients (1 trial; N=882), the RR (95% CI) was 0.93 (0.77-1.12), with moderate certainty. For probiotics in outpatients (1 trial; N=69), RR was 0.32 (0.13-0.78), low certainty. For metformin in outpatients (1 trial; N=450), RR was 0.50 (0.25-0.99), low certainty. For ivermectin in outpatients (1 trial; N=374), RR was 0.93 (0.50-1.71), low certainty. Therapeutic-dose heparin versus prophylactic-dose heparin in inpatients (1 trial; N=571) had RR 1.11 (0.94-1.30) for PCC, low certainty; for cognitive impairment RR was 0.49 (0.22 to 1.07), low certainty; and for HRQoL the MD was 0.12 (-3.22 to 3.46) [range 0-100], moderate certainty. In one trial, metformin (n=569) had no serious adverse events per group; fluvoxamine (n=319), ivermectin (n=406), metformin and fluvoxamine (n=336), and metformin and ivermectin (n=401) had no events in any comparison.

  25. Interventions for the management of long covid (post-covid condition): living systematic review.2024 · systematic review
    Summary

    This living systematic review assessed drug and non-drug interventions for long covid in adults. It included 24 unique trials with 3695 patients, predominantly from the Americas or Europe. One trial (n=114) compared an online CBT programme called “fit after covid” with usual care; moderate certainty evidence suggested CBT probably reduces fatigue (mean difference −8.4, 95% CI −13.11 to −3.69) and probably improves concentration (mean difference −5.2, −7.97 to −2.43). One trial (n=585) compared combined physical and mental health rehabilitation with one session of online advice and support; moderate certainty evidence suggested it probably increases recovery or important improvement (161 more per 1000 patients, 95% CI 61 more to 292 more), improves quality of life (mean difference 0.04, 95% CI 0.00 to 0.08), and reduces depression (mean difference −1.50, −2.41 to −0.59), with little or no effect on physical and cognitive function or anxiety. Intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 95% CI 1.12 to 6.48; n=110). Vortioxetine for eight weeks did not improve cognitive function; coenzyme Q10 500 mg/day for six weeks probably did not improve quality of life (n=119); SIM01 might alleviate fatigue (200 more per 1000 patients, 95% CI 94 more to 336 more; n=463) but probably did not improve quality of life. No instances of post-exertional malaise were reported in the rehabilitation trial; effects on serious adverse events were very uncertain.

  26. Traditional, complementary and integrative medicine for fatigue post COVID-19 infection: A systematic review of randomized controlled trials.2024 · systematic review
    Summary

    This systematic review asked whether traditional, complementary and integrative medicine reduces fatigue after COVID-19. It included thirteen RCTs with 1632 participants; participants from eight RCTs were conducted in China. Searches ran to 12 April 2023. Trials compared herbal and Chinese medicine, probiotics/systemic enzymes, aromatherapy, neuro-meditation, progressive muscle relaxation, and other approaches with placebo, no treatment, or rehabilitation/conventional comparators. For Ludangshen oral liquid versus placebo, fatigue severity was MD -1.90 [-2.38, -1.42], P<0.001; fatigue disappearance RR 4.19 [2.06, 8.53], P<0.001; remission RR 2.04 [1.58, 2.63], P<0.001. Bufei Huoxue capsules versus placebo had MD -14.90 [-24.53, -5.27], P=0.02; Qingjin Yiqi granules plus TCM rehabilitation versus TCM rehabilitation had MD -0.48 [-0.50, -0.46], P<0.001. ADAPT-232/Chisan® versus placebo had MD -1.02 [-2.40, 0.36], P=0.15. Adverse events included abnormal liver function 4 with Bufei Huoxue and 2 with placebo; liver injury 1; diarrhea 1; excessive menstruation 1. None of the trials reported serious adverse events.

  27. Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
    Summary

    This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.

  28. Are probiotic treatments useful on fibromyalgia syndrome or chronic fatigue syndrome patients? A systematic review.2018 · systematic review
    Summary

    This systematic review asked whether probiotics reduce or improve symptoms in patients diagnosed with FMS or CFS. The search used 14 electronic bibliographic databases in February 2016 and included two studies (n=83) in CFS patients; no included study was in FMS patients. The included studies were conducted in Ireland and Canada. Rao et al., 2009 included 48 (28/20) CFS patients and gave Lactobacillus casei strain Shirota for 8 weeks, compared with placebo. It measured faecal Bifidobacteria and Lactobacillus, anxiety with the Beck anxiety inventory and depression with the Beck depression inventory. The probiotic group showed moderate increases in total faecal aerobes and anaerobes and significant increases in total faecal Bifidobacteria and Lactobacillus compared with the placebo group; in the probiotic group 73.7% of faecal samples increased in Bifidobacteria and 26.3% decreased. Anxiety scores showed a significant decrease (P=0.011) in the probiotic group compared with placebo, while depression showed no significant difference (P=0.292). Groeger et al., 2013 included 35 (19/16) CFS patients and gave Bifidobacterium infantis 35624 for 8 weeks, compared with placebo. Probiotic-fed CFS patients showed reduced plasma CRP (P=0.0285), TNF-α (P=0.0214) and IL-6 (P=0.054) compared with placebo-fed patients; 71% in the probiotic group versus 11% in the placebo group had decreased biomarker levels at week 8. Rao et al. reported no significant adverse events in the probiotic or placebo groups; Groeger et al. reported no significant adverse events in the probiotic group but did not assess tolerance. Stopping or worsening was not reported. The authors state that the evidence remains limited and that more research is required.

  29. A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).2018 · systematic review
    Summary

    This systematic review examined probiotic interventions for gastrointestinal and irritable bowel symptoms in CFS/ME. It included 25 studies: 2 investigated interventions in CFS/ME and 23 in IBS. Databases searched were Pubmed, Scopus, Medline (EBSCOHost) and EMBASE. In CFS/ME, Groeger et al. was an RCT with 48 treatment and 22 control participants; Bifidobacterium infantis 35,624 (1 × 1010 CFU, once daily) was compared with placebo. It reported decreases in plasma CRP (p = 0.0285), plasma TNF-α (p = 0.0214), IL-6 (p = 0.054), and LPS-stimulated TNF-α and IL-6 secretion by peripheral blood mononuclear cells (p <0.05). Sullivan Å. et al. was a pilot study of 15 participants given a probiotic mixture; fatigue improved (p = 0.040), while IBS symptoms and SF-12 quality of life were NS. Among included IBS studies, one reported less abdominal pain with placebo (p = 0.005), and a crossover trial reported worsened IBS symptoms with probiotic supplementation (p = 0.012). The authors state CFS/ME studies were limited and of poor quality overall.

  30. Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review.2017 · systematic review
    Summary

    This systematic review asked whether dietary and nutrition interventions affect patient-centred outcomes in adults with CFS/ME. Medline, Cinahl and Scopus were searched from 1994 to May 2016; 17 studies were included, covering 14 different interventions. Included studies were mostly small and from multiple countries. Interventions included ubiquinol-10 150 mg/day for 12 weeks versus placebo; NADH 200 mg/day plus CoQ10 20 mg/day for 8 weeks versus placebo; high cocoa polyphenol chocolate for 8 weeks versus low-polyphenol chocolate; NADH 10 mg/day for 4 weeks versus placebo; probiotics; and an elimination diet. Outcomes were fatigue, quality of life, physical activity and psychological wellbeing. The review reports that many studies did not show therapeutic benefit; improvements in fatigue were observed for NADH, probiotics, high cocoa polyphenol rich chocolate, and a combination of NADH and coenzyme Q10. One included study (n=10) reported decreased fatigue with high cocoa polyphenol chocolate, and one (n=26) reported within-group benefit for NADH versus placebo. Side-effect counts and counts of people who worsened or stopped were not reported. The authors conclude there is insufficient evidence for nutritional supplements and elimination or modified diets to relieve CFS/ME symptoms.

  31. Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review.2017 · systematic review
    Summary

    This systematic review asked whether dietary modification alleviates chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) symptoms. It searched Scopus, CINAHL Plus, Web of Science and PsycINFO from 1994 to 2014 in May 2014, with an update from June 2014 to August 2016, and included 22 studies across animal and human designs. Treatments included D-ribose, probiotic, oral vitamin D3, vitamin and mineral supplements, polynutrient supplementation, magnesium, calcium, ginseng, EFA supplements, glutamine, a low-sugar low-yeast diet, and polyphenols (AMF, EGCG, naringin). D-ribose showed significant improvement in energy levels in compliant analysis (p<0.0001, 95%CI 1.1–2.2), and 65.7% reported improved overall subjective feelings. Probiotic: six of 15 reported subjective improvement and neurocognitive measures improved (p=0.04), but no significant overall change. Vitamin D3 showed no statistically significant improvement in fatigue or inflammatory/oxidative markers. One vitamin/mineral supplement showed improvements in fatigue (p=0.0009) and some quality-of-life measures; another found no significant relationship. Polynutrient supplementation found no significant results. Magnesium improved fatigue at six months (p=0.002) but not at two years; calcium improved fatigue (p=0.01) based on five participants; ginseng was most helpful in 56%. An EFA case study dropped depression scores from 27 to 3 at 16 weeks; an EFA versus sunflower-oil placebo trial found no significant difference. Glutamine showed no significant symptom change; placebo showed decreases in emotionality and sleep problems (p=0.02). The low-sugar low-yeast diet showed no significant difference. Animal polyphenol studies reported significant improvements (p<0.05). The review did not report side effects or withdrawals.

  32. Pharmacological and non-pharmacological management of long COVID.2026 · review
    Summary

    This narrative review synthesized current evidence on non-pharmacological, pharmacological and probiotic management of long COVID, searching Google Scholar and PubMed for peer-reviewed articles "published up to January 2025"; the authors state that no standardized protocols exist. Reported non-pharmacological data included an online-guided 3-month exercise intervention in 62 patients with post-COVID syndrome that "demonstrated benefits in terms of physical performance," although "overall exercise capacity and quality of life did not improve significantly," and a retrospective study of 86 individuals with post-COVID-19 syndrome in which "patients with high adherence to pacing experienced significantly greater recovery and symptom improvement compared to those with low or moderate adherence." In a randomized, double-blind, placebo-controlled, multicenter trial of 200 participants, "By day 14, fatigue resolution was significantly higher in the intervention group compared to the placebo group (91% vs. 15%)," and "The supplements were well tolerated, with no adverse effects reported." In one study of 38 participants, 19 were given VSL#3 and 19 received a placebo, with "Significant improvement in physical functioning, a decrease in fatigue, and alleviation of gastrointestinal problems" in the probiotic group, while "there were no discernible improvements in the symptoms of somatization, anxiety, depression, or performance." In 36 individuals, after 12 weeks of low-dose naltrexone plus NAD+, "fatigue scores were considerably reduced"; "The iontophoresis patches were associated with only mild, short-lived skin irritation in 25% of patients."

  33. Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment.2026 · review
    Summary

    This REVIEW ARTICLE summarizes current understanding of Long COVID, including epidemiology, pathophysiology, organ-specific manifestations, and potential therapeutic approaches. It enrolled no patients and gave no treatment: there was no comparison group, no randomisation, no crossover, no follow-up, and no trial registration. The review reports no results of its own. It discusses cited studies separately: an RCT evaluating a 15-day course of Nirmatrelvir/Ritonavir did not demonstrate clear efficacy for established Long COVID; a randomized trial of plasmapheresis failed to demonstrate significant efficacy; an RCT reported greater improvements in Long COVID symptoms with a synbiotic formulation than with placebo; a non-randomized, open-label study involving 60 patients reported FMT recipients had significant improvements in insomnia and reductions in cortisol levels at 12 weeks; open-label studies reported aspirin, clopidogrel, and apixaban may reduce microclot burden and improve fatigue and dyspnea; a retrospective cohort study found pre-existing oral anticoagulant use did not prevent Long COVID and was associated with a higher risk of post-acute sequelae. The authors state no specific therapeutic agents have been approved; rehabilitation efficacy remains largely based on expert opinion, as RCT evidence is still limited; and few pharmacological treatments have been evaluated in randomized controlled trials.

  34. Exploring the Potential of Dietary Supplements to Alleviate Pain Due to Long COVID.2025 · review
    Summary

    This review explored dietary supplements for pain due to long COVID. It was a review, not a randomised trial; it had no comparison group, and the review itself did not report enrollment, setting, or follow-up. It summarized studies in long COVID or post-COVID syndrome, including studies with 60, 33, 69, 1, 463, 39, 51, 80, 53, 20, and 12 participants. Treatments included acetyl-l-carnitine 500 mg/day, palmitoylethanolamide 600 mg twice daily, PEA-LUT 770 mg, SIM01, VSL#3®, a vitamin D–containing supplement, vitamin D, marine oil enriched in SPMs, a multinutrient supplement, NAC plus guanfacine, and metformin. Durations reported in the recorded findings included 2 weeks, 4 weeks, 6 months, and 10 months. Measured outcomes included pain, persistent post-COVID symptoms, smell recovery, fatigue, memory loss, concentration, gastrointestinal upset, general unwellness, cognitive abilities, physical functioning, anxiety, depression, and long COVID risk. Findings included improvements in pain, fatigue, cognitive symptoms, smell, and some quality-of-life domains; one report noted no improvement in anxiety, depression, performance, or somatization. Recorded side effects were minimal side effects with vitamin D and mild adverse events with LDN; another recorded harms statement concerned antidepressants, and 19 participants discontinued because of adverse events (12 gabapentin, 7 placebo). The authors stated that clinical experience in long COVID-associated pain is still limited.

  35. Subphenotypes of Long COVID and the clinical applications of probiotics.2025 · review
    Summary

    This Review examined Long COVID subphenotypes and probiotic applications; it reports no own study participants. A clinical study in Hong Kong involving 463 patients reported relative improvements with SIM01 in fatigue (47 %), memory loss (56 %), difficulty in concentration (62 %), gastrointestinal distress (30 %), and general illness (31 %). A randomized, double-blind, placebo-controlled study of 38 volunteers with clinically significant fatigue reported that VSL#3® treatment resulted in a statistically significant decrease in fatigue from the start to the end of treatment, significant amelioration in physical functioning, and improvement in gastrointestinal symptoms, but was not associated with improvements in symptoms of anxiety, depression, performance, or somatization. A randomized, double-blind, placebo-controlled trial in 182 people reported LGG was associated with a lower risk of sickness symptoms and a statistically significant decrease in COVID-19 diagnoses, while overall prevalence of COVID-19 diagnosis did not vary significantly. A study of 58 patients reported the OB+ group’s proportion experiencing fatigue was significantly lower (p < 0.01), and 70.7 % of the OB-group reported feeling fatigued. In a randomised trial of 147 individuals, PC recipients had a three-fold reduction in cough scores, a nearly two-fold reduction in mean fatigue scores, and a more than two-fold improvement in overall well-being scores; two individuals (1.5 %) experienced mildly elevated bloating. A 126-participant study reported improvements in subjective well-being, exhaustion, and cough over the 30-day period; two patients (1.5 %) complained of mildly elevated bloating and diarrhea.

  36. Long COVID and gut microbiome: insights into pathogenesis and therapeutics.2025 · review
    Summary

    This is a review, with no own participants, of gut microbiome alterations and microbiome-based therapeutics in post-acute coronavirus disease 2019 syndrome (PACS). It searched PubMed/MEDLINE and Google Scholar for literature published between December 2019 and December 2024, including observational studies, animal studies, clinical trials, case reports, systematic reviews, and meta-analyses. The review summarizes a randomized, double-blind, placebo-controlled trial (n = 463) in which a synbiotic preparation (SIM01) was given orally for 6 months; compared with placebo, significantly higher proportions in the SIM01 group had alleviation of fatigue, memory loss, difficulty in concentration, gastrointestinal upset, and general unwellness. It also summarizes a randomized trial (n = 200) of probiotics with three Bacillus species plus systemic enzymes for 14 days, with a significantly higher proportion having fatigue resolution on day 14; a synbiotic trial (n = 52) for 35 days found no significant difference in post-COVID symptoms at 6 months; a probiotic trial (n = 73) for 28 days found no significant improvement in post-COVID symptoms at 3 months versus placebo. A non-randomized FMT study (n = 60) reported a significantly higher proportion with insomnia remission at 12 weeks versus no treatment. A case report (n = 11) described FMT via oral capsules. No numerical adverse-event counts were recorded for these trials; one trial reported no statistical difference in adverse event rates between SIM01 and placebo.

  37. Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
    Summary

    This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.

  38. A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery.2025 · review
    Summary

    This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.

  39. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  40. A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID.2025 · review
    Summary

    This perspective review assessed metformin for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID (LC); the authors enrolled no patients and reported no primary study data. It discusses mechanisms and summarizes other studies. Bramante et al. was described as a multiarm, multiagent, parallel-grouped, phase three trial with an initial n of 6602; confirmed LC by day 300 was 8.3% of that initial n, and the metformin group showed a reduction of 41% when started within 3 days of COVID-19 symptom onset. Reis et al. reported a relative risk of 1.14 (0.73–1.81) for metformin worsening the primary outcome, with 21.9% of the Metformin group dropping out compared with 11.8% of the placebo group. Ventura-Lopez et al. reported reduced acute COVID-19 severity and viral load with 620 mg Metformin Glycinate twice daily. A Hubei retrospective cohort reported higher acidosis and lactic acidosis in the metformin group (2.95%, 1.77% vs 1.5%, 0.75%), lower heart failure (HR 0.61 p = 0.006) and ARDS (HR 0.66 p = 0.028), and no significant difference in mortality. Bullón treated six fibromyalgia patients with 200 mg/day of metformin, with reduced symptoms on the Fatigue Inventory Questionnaire and a significant decrease in fatigue. The review also lists dose-dependent side effects such as diarrhea, nausea and abdominal pain in 20% of cases. The authors state more research is needed to refine dosing and delivery methods.

  41. The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.2025 · review
    Summary

    This review examined probiotics and postbiotics for post-COVID-19 syndrome. It was a review, not a primary trial; no overall participant count was reported. The literature search used databases available through the John Paul II Catholic University of Lublin library system and covered publications from January 2020 to June 2025. Among the named studies, Caprioli et al. was a randomized clinical trial with a placebo: 38 participants, 19 received a probiotic supplement and the other half took a placebo for 4 weeks; the probiotic group showed a significant decrease in the Chalder’s fatigue index, while the placebo group showed no change in perceived fatigue. Santinelli et al. reported 58 hospitalized COVID-19 patients: 24 received Sivomixx800R during hospitalization and 34 received only standard treatment; six months after discharge, 70.7% reported fatigue, and the probiotic group had a significantly lower percentage of fatigue reports than the control group. Another recorded study gave ProbioSEB CSC3 with ImmunoSEB’s systemic enzymes; after two weeks, fatigue symptoms disappeared in 91% of participants, and the experimental group had a significant reduction in physical and mental fatigue at all stages compared with the control group. The review also recorded 'no apparent increase in the risk of side effects.'

  42. The potential therapeutic approaches targeting gut health in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a narrative review.2025 · review
    Summary

    This narrative review searched English peer-reviewed literature from January 1995 to January 2025 via PubMed, Scopus, and Web of Science to synthesize data on gut microbiota, inflammatory markers, and therapeutic outcomes in ME/CFS. The review did not report enrolling patients. It describes probiotic studies: an Italian pilot 8-week course improved well-being and reduced inflammation; in 15 ME/CFS patients, three strains improved neurocognitive function but no significant fatigue or physical activity reduction in only nine patients; Bifidobacterium infantis 35,624 in 48 patients lowered CRP, TNF-α, and IL-6. A 12-week Ubiquinol-10 randomized trial reported no significant fatigue improvement but reduced night-time awakenings; a 16-week randomized placebo-controlled trial of oral melatonin (1 mg) and zinc (10 mg) in 50 patients showed reductions in physical fatigue and improved quality of life. FMT: a retrospective study of 60 patients reported 70% response after four weeks and 58% maintained resolution for 15–20 years; another reported 17 of 21 patients with at least 60% improvement; a randomized placebo-controlled pilot in 11 patients (5 universal donor, 6 autologous) found no notable quality-of-life differences at 1 and 6 months. A Norway survey reported about 80% declined after graded exercise therapy; structured moderate activity over 12 to 26 weeks reduced fatigue compared with conventional/passive therapies; after a maximal exercise test, pain, fatigue, and confusion changed, with Clostridium in blood at 15 min and Bacilli increased at 48 h. Authors state current research lacks comprehensive insights and studies often produce conflicting findings, with varied diagnostic criteria and small samples.

  43. Nutritional And Dietary Interventions For The Treatment Of Chronic Fatigue Syndrome2018 · review
    Summary

    This review asked whether nutritional and dietary interventions can minimize symptoms of chronic fatigue syndrome (CFS/ME); 22 researches from EBSCO and Google Scholar were analyzed. It describes Castro-Marrero et al. 2015: 113 patients were enrolled at the CTS Clinical Unit (Vall d'Hebron Hospital, Barcelona, Spain); after 8 weeks of CoQ10 and NADH treatment, fatigue in people with CFS decreased compared to placebo. Ostojic et al. 2016 gave GAA (2.4 g per day) or placebo for three months: general fatigue and musculoskeletal pain were not affected; muscle and oxygen strength improved; daily physical activity and active energy expenditure were ineffective; GAA reduced physical and mental fatigue; a significant effect on muscle pain and fatigue was not reported; no side effects were reported. Rao et al. 2009 observed a reduction in aggression after 8 weeks of Lactobacillus casei Shirota. Vermeulen et al. 2004 studied 90 patients with CFS for 24 weeks: improvement was 59% in the ALC group, 63% in the PLC group and 37% in the ALC + PLC group; 10% in the ALC group, 3% in the PLC group and 16% in the ALC + PLC group felt worse; after 2 weeks of discontinuation, 52% in the ALC group, 50% in the PLC group and 40% in the ALC + PLC group deteriorated; 8 patients were excluded due to side effects (3 in the ALC group, 2 in the PLC group and 3 in the ALC+PLC group) because they experienced excessive excitability and insomnia. Limitations: relatively small experiments.

  44. The Role of the Microbiota and Potential for Dietary Intervention in Chronic Fatigue Syndrome2016 · review
    Summary

    This review examined the role of gut microbiota and potential dietary intervention with probiotics in chronic fatigue syndrome (CFS). It reports no primary trial of its own: no comparison group, no randomisation, and no enrolled or analysed participant counts. The review describes studies in people with CFS; study locations and participant numbers were not reported. Gaab et al., 2005 is reported as showing a positive effect of Lactobacillus casei on emotional and anxiety symptoms. Raber et al., 1998 is reported as showing a significant improvement in neurocognitive functions with L. paracasei, L. acidophilus and B. lactis, but not in fatigue and physical activity scores. Rao et al., 2009 is described as a clinical study in individuals with CFS; L. casei strain Shirota at 24 billion cfu/day was found at 8 weeks to increase Lactobacillus and Bifidobacterium and to produce a significant decrease in anxiety symptoms. The review states probiotics have been shown to be well tolerated with few side effects. The authors conclude that probiotics appear to provide some benefit in CFS, but that there is not enough clinical evidence recommending their therapeutic use for CFS at this time, that randomised control trials are lacking, and that knowledge of long-term efficacy is lacking. Stated limitations include inadequate sample size, poor study design, heterogeneity of CFS patients, and use of multiple probiotic strains and doses across studies.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime